What it is used for

TIMENTIN is indicated in the treatment of serious infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: Septicaemia (and bacteraemia) cases caused by beta-lactamase producing organisms including strains of Klebsiella pneumoniae, E.coli, Staphylococcus aureus and Pseudomonas aeruginosa. Lower Respiratory Infections cases caused by beta-lactamase producing susceptible organisms including strains of Staphylococcus aureus, Haemophilus influenzae and Klebsiella pneumoniae. Bone and Joint Infections cases caused by beta-lactamase producing susceptible organisms including strains of Staphylococcus aureus. Skin and Skin Structure Infections cases caused by beta-lactamase producing susceptible organisms including strains of Staphylococcus aureus, Klebsiella pneumoniae and E. coli. Urinary Tract Infections cases caused by beta-lactamase producing susceptible organisms including strains of E.coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Staphylococcus aureus. Gynaecological Infections including cases caused by beta-lactamase producing susceptible organisms including strains of Klebsiella pneumoniae, Staphylococcus aureus and Staphylococcus epidermidis. While TIMENTIN is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by ticarcillin susceptible and beta-lactamase producing ticarcillin resistant organisms. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to TIMENTIN. Therapy with TIMENTIN may, however, be initiated before results of such tests are known when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above; however, once these results become available, appropriate therapy should be continued. Based on the in vitro synergism between ticarcillin and gentamicin sulphate/tobramycin sulphate/amikacin sulphate against certain strains of Pseudomonas aeruginosa, combined therapy has been successful. TIMENTIN may be used as combination therapy concurrently with the aminoglycosides but both drugs should be used in full therapeutic doses. As soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted as indicated. Results of susceptibility tests showing synergy between ticarcillin and one aminoglycoside should not be extrapolated to combination with another aminoglycoside. Prophylactic Use: TIMENTIN may be administered perioperatively (preoperatively, intraoperatively and postoperatively) to patients undergoing abdominal hysterectomy or elective colorectal surgery when there is a significant risk of surgery related postoperative infections. If signs of postsurgical infection should appear, these should be treated with appropriate therapy.

How to take it

The way to take this medicine is: Intravenous. This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.

• Store below 25 degrees Celsius
• Shelf lifetime is 18 Months.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.

Visual appearance

A fine white powder

Do I need a prescription?

This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine. open tool tip to find out more